Share on

Global Plasma Fractionation Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Product (Albumin, Immunoglobulin, Factor VIII and Protease Inhibitors), Application (Neurology, Hematology, Rheumatology, Pulmonology and Immunology), End-Users and Region (North America, Europe, APAC, Latin America, Middle East and Africa) – Industry Forecast (2022 to 2027).

Published: January, 2022
ID: 2719
Pages: 175
Formats: report pdf report excel report power bi report ppt

Global Plasma Fractionation Market Size (2022 to 2027)

As per our report, the global plasma fractionation market size is estimated to be growing at a CAGR of 7.2% during the forecast period. This market is expected to be worth USD 33.83 billion by 2027 and USD 23.89 billion in 2022.

Plasma is the liquid portion of blood. It consists of red cells, white cells, and platelets suspended in it and contains thousands of distinct proteins and other substances like electrolytes, minerals, hormones, etc., necessary for the human body's normal function. Plasma helps in maintaining blood pressure and body temperature regulation.

Impact of COVID-19 on the global plasma fractionation market:

The COVID-19 pandemic is expected to drive significant growth in the global plasma fractionation market. Some countries are working with plasma fractionation techniques to discover new cures and diagnostic methodologies for the novel coronavirus. The use of convalescent plasma as a treatment for COVID-19 positive patients may be a viable option. Plasma is extracted from a previously infected person's blood and then given to an actual patient. As a result of the plasma containing vital antibodies to combat the infection, the patient receives passive immunization. Octapharma, a major pharmaceutical company, is putting its knowledge to use in the search for new COVID-19 drugs. In order to improve a possible plasma-derived hyperimmune immunoglobulin treatment, it is working with leading plasma fractionation players. The alliance is looking at developing an unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin. Patients with serious COVID-19 symptoms can benefit from the treatment. The company gathers convalescent plasma to help fund preclinical and clinical research on whether the anti-SARS-CoV-2 hyperimmune immunoglobulin is useful in treating COVID-19. The spread of the COVID-19 pandemic has also resulted in a reduction in the number of blood donors and plasma collections in certain countries, which has hampered the economy by causing a shortfall in raw material availability.

The COVID-19 pandemic has serious consequences for blood transfusion. According to the NIH COVID-19 Care Guidelines panel, there is insufficient evidence to recommend either for or against the use of monoclonal antibodies for the treatment of outpatients with mild to moderate COVID. To maximize revenue during the pandemic, players in the plasma fractionation industry are increasing their investments in potential immunoglobulin covid-19 vaccine production applications. In 2020, several leading biopharmaceutical firms joined forces to find therapeutic alternatives to the current global pandemic. Although there is little known about plasma-derived therapies in general, the COVID-19 pandemic has shed light on this form of therapy and highlighted its wider applications in everyday medicine. The importance of this field of pharmaceutical medicine and healthcare became clear as its understanding of the novel coronavirus increased. In response to the pandemic, the major global players in plasma-derived medicinal products, formed the CoVIg-19 Plasma Alliance to accelerate the production of investigational hyperimmune immunoglobulin therapy for the treatment of COVID-19. Convalescent plasma has been commonly used to treat coronavirus disease 2019 (Covid-19), It is unclear if convalescent plasma with high antibody levels, as opposed to low antibody levels, is associated with a lower risk of death.


Inclined to a variety of rare diseases that require the use of plasma derivatives is expected to drive the global plasma fractionation market growth.

A rare disease, according to NORD, is a disease or condition that affects less than 200,000 Americans. More than 7,000 rare diseases affect more than 30 million Americans collectively. This figure represents the prevalence rate of selected rare diseases in businesses worldwide in 2017. In that year, the global prevalence of multiple sclerosis was 90 per 100,000 people. Rare diseases account for 35% of all deaths in the first year of life. Plasma-derived products are among the safest biological therapies available; they are efficiently and strictly controlled in all aspects of their clinical use and supply chain in developed countries.

Y-O-Y growth in the prevalence of respiratory diseases across the world is another significant factor boosting the global plasma fractionation market growth.

Respiratory disorders such as asthma, COPD, and new acute Coronavirus disease. According to NIH, Plasma from COVID-19-recovered donors may produce antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may help suppress the virus and alter the inflammatory response. More than 70,000 patients in the United States have received COVID-19 convalescent plasma through the Mayo Clinic's Expanded Access Program (EAP), which was created to provide widespread access to investigational convalescent plasma.

The growing aging population with related blood-related ailments is also set to drive the global plasma fraction market growth.

Globally, the population is aging at an alarming pace in emerging countries such as India, China, and Japan, etc. According to WHO, people are living longer lives all over the world—between 2015 and 2050, the proportion of the world's population over 60 years old would nearly double from 12% to 22%. By 2050, low- and middle-income countries will house 80 percent of the elderly. France had nearly 150 years to adjust to a 10% increase in the proportion of the population over 60 years old.

Y-O-Y growing prevalence of Hemoglobin disorders such as sickle cell disease and thalassemia are expected to accelerate the global plasma fractionation market.

Hemoglobinopathies are the most common genetically inherited disorders. According to the World Health Organization (WHO), roughly 5% of the world's population is a carrier of hereditary hemoglobin (Hb) disorders. About 42 million people are carriers per year, and over 12,000 babies are born with a major and clinically meaningful hemoglobinopathy. Thalassemia is one of the most lethal diseases on the planet. It is a hereditary blood condition affecting approximately 100,000 Indian patients.

Increasing usage of immunoglobulins in different areas is a significant factor driving the global plasma fractionation market.

Factors such as increasing incidence of immune and bleeding disorders, growing prevalence of Alpha-1 Antitrypsin deficiency, and the increasing use of immunoglobulins, which are antibodies, are propelling the global plasma fractionation market. Additionally, the emergence of novel and innovative products to treat immunological deficiencies, inherited metabolic disorders, and trauma and the rising number of FDA approvals provide lucrative opportunities for the growth of plasma fractionation globally.


Increasing use of recombinant proteins and products serving as a replacement for plasma products and the risk factors associated with them, escalating prices of plasma derivatives, unfavorable reimbursement policies, increased use in prophylactic therapies are likely to restrain the growth of the global plasma fractionation market. Regulatory authorities strictly govern plasma products since they are made from entire blood. Stringent regulations governing the manufacturing plant, the source of whole blood, and the isolation procedure, among other things, could limit the market's expansion. Such strict policies will affect the product's production and processing time and the market's growth in the coming years.

Furthermore, the shortage of plasma protein products is caused due to the high cost of imported products, and a lack of domestic industrial fractionation capability, and a scarcity of high-quality plasma for fractionation in the local market has hampered the growth of the plasma fractionation market. Limited reimbursements, the high cost of plasma products, and the introduction of recombinant alternatives are impeding the growth of the market.




Market Size Available

2021 to 2027

Base Year


Forecast Period

2022 to 2027

Segments Analysed

By Product, Application, End-User, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, Middle East & Africa


This research report on the global plasma fractionation market has been segmented and sub-segmented based on the product, application, end-user, and region.

Plasma Fractionation Market – By Product:

  • Albumin
  • Immunoglobulin
  • Factor VIII
  • Protease Inhibitors

The immunoglobulin segment is expected to dominate the global plasma fractionation market by contributing a significant share based on the product. Factors such as the increasing focus of immunology research and the growing adoption of immunoglobulin in primary and secondary immune deficiencies, inflammatory diseases, and autoimmune diseases are helping this segment experience to accumulate significantly during the forecast period.

Plasma Fractionation Market – By Application:

  • Neurology
  • Hematology
  • Rheumatology
  • Pulmonology
  • Immunology

Based on the application, the neurology segment dominates the plasma fractionation market by contributing a significant share and is expected to be the rapidly growing segment due to increasing demand for plasma fractionation products for the treatment and improving plasma fractionation applications products in the neurology field.

Plasma Fractionation Market – By End-user:

  • Hospital
  • Clinical Laboratories

Plasma Fractionation Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

As of 2021, the North American plasma fractionation market accounted for the major share of the global market, with the U.S. accounting for a significant share. The presence of a high number of registered hemophilic patients and increasing the use of immunoglobulins in neurologic disorders are much supporting the market to grow in this region. Europe comes in second in terms of market share due to rising awareness about blood-related diseases and the swift availability of treatment in terms of plasma fractionation.

The European plasma fractionation market is projected to showcase a CAGR of 6.1% from 2022 to 2027.

On the other hand, the Asia-Pacific plasma fractionation market is estimated to grow at the highest CAGR during the forecast period, majorly because of the presence of more significant elderly population numbers leading to a higher incidence of blood disorders.

The Latin American plasma fractionation market size was valued at USD 6.51 billion in 2022.

The plasma fractionation market in the MEA region is forecasted to be worth USD 2.82 billion by 2027.


Some of the notable companies playing a leading role in the global plasma fractionation market profiled in this report are CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), Bio Products Laboratory (U.K.), Sanquin (Netherland), China Biologic Products, Inc. (China), Biotest AG (Germany), and Laboratoire Français du Fractionnement et des Biotechnologies (France).


Please wait. . . . Your request is being processed


How big is the plasma fractionation market?

The global market size for plasma fractionation was worth USD 23.89 billion in 2022 and is estimated to grow by USD 33.83 billion by 2027.

What is the growth rate of the global plasma fractionation market?

The global plasma fractionation market size is forecasted to be growing at a CAGR of 7.2% CAGR from 2022 to 2027.

Does this report include the impact of COVID-19 on the plasma fractionation market?

Yes, we have studied and included the COVID-19 impact on the global plasma fractionation market in this report.

Who are the major companies in the global plasma fractionation market?

CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), Bio Products Laboratory (U.K.), Sanquin (Netherland), China Biologic Products, Inc. (China), Biotest AG (Germany), and Laboratoire Français du Fractionnement et des Biotechnologies (France) are a few of the noteworthy players in the global plasma fractionation market.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample